{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:13:43Z","timestamp":1787670823232,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004740","name":"Fondazione del Monte di Bologna e Ravenna","doi-asserted-by":"publisher","award":["760bis\/2019"],"award-info":[{"award-number":["760bis\/2019"]}],"id":[{"id":"10.13039\/501100004740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10072-022-06485-y","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T06:02:55Z","timestamp":1667973775000},"page":"565-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Screening for impulse control disorders in Parkinson\u2019s disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6399-9999","authenticated-orcid":false,"given":"Manuela","family":"Contin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Lopane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Sambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"De Massis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Sermi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Persichella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Cortelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Calandra-Buonaura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"6485_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-01(2017)7-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm (Vienna) 124:901\u2013905. https:\/\/doi.org\/10.1007\/s00702-01(2017)7-1686-y","journal-title":"J Neural Transm (Vienna)"},{"key":"6485_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1517\/13543784.2014.869209","volume":"23","author":"F Blandini","year":"2014","unstructured":"Blandini F, Armentero MT (2014) Dopamine receptor agonists for Parkinson\u2019s disease. Expert Opin Investig Drugs 23:387\u2013410. https:\/\/doi.org\/10.1517\/13543784.2014.869209","journal-title":"Expert Opin Investig Drugs"},{"key":"6485_CR3","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (4th ed., Text Revision), Washington, DC. https:\/\/doi.org\/10.1176\/appi.books.9780890423349.","DOI":"10.1176\/appi.books.9780890423349"},{"key":"6485_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, David AS, Evans AH, Grant JE, Stacy M (2015) Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov Disord 30:121\u2013127. https:\/\/doi.org\/10.1002\/mds.26016","journal-title":"Mov Disord"},{"key":"6485_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/jnnp-2019-322453","volume":"91","author":"MJ Kelly","year":"2020","unstructured":"Kelly MJ, Baig F, Hu MT, Okai D (2020) Spectrum of impulse control behaviours in Parkinson\u2019s disease: pathophysiology and management. J Neurol Neurosurg Psychiatry 91:703\u2013711. https:\/\/doi.org\/10.1136\/jnnp-2019-322453","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6485_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2019.02.04","volume":"59","author":"I Rektorova","year":"2019","unstructured":"Rektorova I (2019) Current treatment of behavioral and cognitive symptoms of Parkinson\u2019s Disease. Parkinsonism Relat Disord 59:65\u201373. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.04","journal-title":"Parkinsonism Relat Disord"},{"key":"6485_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11910-013-0386-8","volume":"13","author":"CC Probst","year":"2013","unstructured":"Probst CC, van Eimeren T (2013) The functional anatomy of impulse control disorders. Curr Neurol Neurosci Rep 13:386. https:\/\/doi.org\/10.1007\/s11910-013-0386-8","journal-title":"Curr Neurol Neurosci Rep"},{"key":"6485_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/syn.21805","volume":"69","author":"P Seeman","year":"2015","unstructured":"Seeman P (2015) Parkinson\u2019s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69:183\u2013189. https:\/\/doi.org\/10.1002\/syn.21805","journal-title":"Synapse"},{"key":"6485_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2018.11.007","volume":"61","author":"M Contin","year":"2019","unstructured":"Contin M, Lopane G, Mohamed S, Calandra-Buonaura G, Capellari S, De Massis P, Nassetti S, Perrone A, Riva R, Sambati L, Scaglione C, Cortelli P (2019) Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 61:111\u2013117. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.007","journal-title":"Parkinsonism Relat Disord"},{"key":"6485_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fneur.2019.00351","volume":"10","author":"EM Gatto","year":"2019","unstructured":"Gatto EM, Aldinio V (2019) Impulse control disorders in Parkinson\u2019s disease. A brief and comprehensive review. Front Neurol 10:351. https:\/\/doi.org\/10.3389\/fneur.2019.00351","journal-title":"Front Neurol"},{"key":"6485_CR11","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"30","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V (2009) Validation of the questionnaire for impulsive compulsive disorders in Parkinson\u2019s disease. Mov Disord 30:1461\u20131467. https:\/\/doi.org\/10.1002\/mds.22571","journal-title":"Mov Disord"},{"key":"6485_CR12","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30:1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"6485_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427\u2013442. https:\/\/doi.org\/10.1212\/wnl.17.5.427","journal-title":"Neurology"},{"key":"6485_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/mds.23096","volume":"25","author":"CG Goetz","year":"2010","unstructured":"Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM (2010) Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale: (MDS-UPDRS). Mov Disord 25:1190\u20131194. https:\/\/doi.org\/10.1002\/mds.23096","journal-title":"Mov Disord"},{"key":"6485_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.parkreldis.2010.11.015","volume":"17","author":"K Papay","year":"2011","unstructured":"Papay K, Mamikonyan E, Siderowf AD, Duda JE, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Weintraub D (2011) Patient versus informant reporting of ICD symptoms in Parkinson\u2019s disease using the QUIP: Validity and variability. Parkinsonism Relat Disord 17:153\u2013155. https:\/\/doi.org\/10.1016\/j.parkreldis.2010.11.015","journal-title":"Parkinsonism Relat Disord"},{"key":"6485_CR16","unstructured":"Zennaro A, Ferracuti S, Lang M, Sanavio E (2008) MCMI-III - Millon Clinical Multiaxial Inventory-III. Manuale. Adattamento italiano, Giunti OS FI Organizzazioni Speciali."},{"key":"6485_CR17","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::aid-jclp2270510607>3.0.co;2-1","volume":"51","author":"JH Patton","year":"1995","unstructured":"Patton JH, Stanford MS, Barratt E (1995) Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol 51:768\u2013774. https:\/\/doi.org\/10.1002\/1097-4679(199511)51:6%3c768::aid-jclp2270510607%3e3.0.co;2-1","journal-title":"J Clin Psychol"},{"key":"6485_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/87565649109540545","volume":"77","author":"G Measso","year":"1993","unstructured":"Measso G, Cavarzeran F, Zappal\u00e0 G, Lebowitz BD, Crook TH, Pirozzolo FJ, Amaducci LA, Massari D, Grigoletto F (1993) The mini-mental state examination: Normative study of an Italian random sample. Dev Neuropsychol 77:77\u201385. https:\/\/doi.org\/10.1080\/87565649109540545","journal-title":"Dev Neuropsychol"},{"key":"6485_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s10072-005-0443-4","volume":"26","author":"I Appollonio","year":"2005","unstructured":"Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, Forapani E, Russo A, Nichelli P (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108\u2013116. https:\/\/doi.org\/10.1007\/s10072-005-0443-4","journal-title":"Neurol Sci"},{"key":"6485_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","volume":"7","author":"S Schade","year":"2020","unstructured":"Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov Disord Clin Pract 7:343\u2013345. https:\/\/doi.org\/10.1002\/mdc3.12921","journal-title":"Mov Disord Clin Pract"},{"key":"6485_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/ene.13034","volume":"23","author":"A Rizos","year":"2016","unstructured":"Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, Henriksen T, Falup-Pecurariu C, Silverdale M, Durner G, R\u00f8kenes Karlsen K, Grilo M, Odin P, Chaudhuri KR (2016) A European multicentre survey of impulse control behaviours in Parkinson\u2019s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 23:1255\u20131261. https:\/\/doi.org\/10.1111\/ene.13034","journal-title":"Eur J Neurol"},{"key":"6485_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.parkreldis.2012.06.005","volume":"18","author":"J Joutsa","year":"2012","unstructured":"Joutsa J, Martikainen K, Vahlberg T, Kaasinen V (2012) Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson\u2019s disease. Parkinsonism Relat Disord 18:1079\u20131083. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.06.005","journal-title":"Parkinsonism Relat Disord"},{"key":"6485_CR23","doi-asserted-by":"publisher","first-page":"17m11612","DOI":"10.4088\/JCP.17m11612","volume":"79","author":"MR Lo Monaco","year":"2018","unstructured":"Lo Monaco MR, Petracca M, Weintraub D, Fusco D, Liperoti R, Zuccal\u00e0 G, La Carpia D, Vetrano DL, Genovese D, Pisciotta MS, Brandi V, Padua L, Imbimbo I, Ricciardi D, Bernabei R, Silveri MC, Laudisio A, Bentivoglio AR (2018) Prevalence of impulsive-compulsive symptoms in elderly Parkinson\u2019s Disease patients: a case-control study. J Clin Psychiatry 79:17m11612. https:\/\/doi.org\/10.4088\/JCP.17m11612","journal-title":"J Clin Psychiatry"},{"key":"6485_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/mds.27689","volume":"34","author":"AH Evans","year":"2019","unstructured":"Evans AH, Okai D, Weintraub D, Lim SY, O\u2019Sullivan SS, Voon V, Krack P, Sampaio C, Post B, Leentjens AFG, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A, Members of the International Parkinson and Movement Disorder Society (IPMDS) Rating Scales Review Committee (2019) Scales to assess impulsive and compulsive behaviors in Parkinson\u2019s disease: critique and recommendations. Mov Disord 34:791\u2013798. https:\/\/doi.org\/10.1002\/mds.27689","journal-title":"Mov Disord"},{"key":"6485_CR25","volume-title":"Interpretative Guide to the Millon Clinical Multiaxal Inventor","author":"JP Choca","year":"1997","unstructured":"Choca JP, Van Denburg EJ (1997) Interpretative Guide to the Millon Clinical Multiaxal Inventor, 2nd edn. American Psychological Association","edition":"2"},{"key":"6485_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","volume":"41","author":"M Grall-Bronnec","year":"2018","unstructured":"Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, Zreika N, Derkinderen P, Challet-Bouju G (2018) Dopamine agonists and impulse control disorders: a complex association. Drug Saf 41:19\u201375. https:\/\/doi.org\/10.1007\/s40264-017-0590-6","journal-title":"Drug Saf"},{"key":"6485_CR27","doi-asserted-by":"publisher","unstructured":"Canesi M, Lavolpe S, Cereda V, Ranghetti A, Maestri R, Pezzoli G, Rusconi ML (2020) Hypomania, depression, euthymia: new evidence in Parkinson\u2019s Disease. Behav Neurol Article ID 5139237, 8. https:\/\/doi.org\/10.1155\/2020\/5139237.","DOI":"10.1155\/2020\/5139237"},{"key":"6485_CR28","volume-title":"The Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Manual for Administration and Scoring","author":"JN Butcher","year":"1989","unstructured":"Butcher JN, Dahlstrom WG, Graham JR, Tellegen A, Kaemmer B (1989) The Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Manual for Administration and Scoring. University of Minnesota Press, Minneapolis, MN"},{"key":"6485_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/WNN.0b013e31824b4103","volume":"25","author":"K Farnikova","year":"2012","unstructured":"Farnikova K, Obereigneru R, Kanovsky P, Prasko J (2012) Comparison of personality characteristics in Parkinson disease patients with and without impulse control disorders and in healthy volunteers. Cogn Behav Neurol 25:25\u201333. https:\/\/doi.org\/10.1097\/WNN.0b013e31824b4103","journal-title":"Cogn Behav Neurol"},{"key":"6485_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.psychres.2006.03.011","volume":"149","author":"A Fossati","year":"2007","unstructured":"Fossati A, Barratt ES, Borroni S, Villa D, Grazioli F, Maffei C (2007) Impulsivity, aggressiveness, and DSM-IV personality disorders. Psychiatry Res 149:157\u2013167. https:\/\/doi.org\/10.1016\/j.psychres.2006.03.011","journal-title":"Psychiatry Res"},{"key":"6485_CR31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/mds.22472","volume":"24","author":"G Santangelo","year":"2009","unstructured":"Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P (2009) Cognitive dysfunction and pathological gambling in patients with Parkinson\u2019s disease. Mov Disord 24:899\u2013905. https:\/\/doi.org\/10.1002\/mds.22472","journal-title":"Mov Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06485-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06485-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06485-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T07:14:32Z","timestamp":1673853272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06485-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6485"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06485-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"23 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Area Vasta Emilia Centro (CE20072) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Standard protocol approvals, registrations, and patient consents"}},{"value":"G. C.-B. has received honoraria for speaking from Abbvie Italia, Bial Italia, and Zambon Italia. For the remaining authors, none were declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}